Abstract
Penfluridol has robust antipsychotic efficacy and is a first-generation diphenylbutylpiperidine. Its effects last for several days after a single oral dose and it can be administered once a week to provide better compliance and symptom control. Recently; strong antitumour effects for penfluridol were discovered in various cancer cell lines; such as breast; pancreatic; glioblastoma; and lung cancer cells via several distinct mechanisms. Therefore; penfluridol has drawn much attention as a potentially novel anti-tumour agent. In addition; the anti-cancer effects of penfluridol have been demonstrated in vivo: results showed slight changes in the volume and weight of organs at doses tested in animals. This paper outlines the potential for penfluridol to be developed as a next-generation anticancer drug.
Original language | English |
---|---|
Article number | 3659 |
Journal | Molecules |
Volume | 24 |
Issue number | 20 |
DOIs | |
State | Published - 11 Oct 2019 |
Keywords
- Antipsychotic
- Autophagy
- Drug repositioning
- Glioblastoma
- Hallmarks of cancer
- Penfluridol